Interview with Kalman Petro, Managing Director, Actavis BV
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Address: Lage Mosten 33, 4822 NK, Noord-Brabant,Netherlands
Tel: +31-765731140
Web: http://www.ucbpharma.nl/home
As a global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.1 billion in 2009, UCB aspires to be the patient-centric global biopharmaceutical leader transforming the lives of people living with severe diseases.
By integrating biology (bio) and chemistry (pharma), we can gain much deeper insights into disease pathways, including the complexities of severe diseases, as well as producing more potent, cost-effective drugs.
The unique combination of expertise in large, antibody-based molecules and small, chemically-derived molecules places us in a strong position to realise this ambition. Cimzia®, our New Biological Entity (NBE), targeted at Crohn’s disease and rheumatoid arthritis, is one of the first fruits of this synergy of biology and chemistry.
UCB’s medicines are making a real difference to the lives of people all over the world. Some of our products are among the leaders in their field.
Vimpat® (lacosamide): Epilepsy
Keppra® (levetiracetam): Epilepsy
Neupro® (rotigotine): Parkinson’s disease, Restless Legs Syndrome
Nootropil® (piracetam): Regulating cerebral functions
Metadate CD™ (methylphenidate HCl) (CII): Attention Deficit Hyperactivity Disorder (ADHD)
Cimzia® (certolizumab pegol): Crohn’s disease, Rheumatoid arthritis
Xyzal® (levocetirizine): Allergies
Zyrtec® (cetirizine):Allergies
Tussionex™ (hydrocodone polistirex and chlorpheniramine polistirex) (CIII): Respiratory disease
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination…
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
As the founder of the Institute of Young Entrepreneurs at the Delft University of Technology and an enthusiastic promoter of innovation and new technologies, what do you believe distinguishes a…
We do not often meet companies that have been successful at retaining their manufacturing facilities in the Netherlands. How and why did former Katwijk Farma -and now Apotex- succeed to…
Pfizer is well placed for the next generation of growth. Coming off great M&A’s and now restructuring internally, (from the country structure to the business units). After closing 2010, the…
Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths…
While doing our research we couldn’t help but notice that you are quite passionate about issues related to healthcare and an avid proponent of healthcare reform. In this vein, what…
IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market?…
As the chairman of a consortium that has been working towards both medical and technological progress in the region, how have you seen this progress taking place in the Netherlands…
Your role as Chair of the Executive Board is a mix between CEO and CMO. On a daily basis, which do you see yourself as more – the Chief Executive…
Deloitte is renowned for its strong network of international expertise. Yet every market has its own particularities… Having spent 16 years with the company, in your opinion, what is it…
See our Cookie Privacy Policy Here
